143360-00-3
143360-00-3 structure
- Name: SMIP004
- Chemical Name: N-(4-butyl-2-methylphenyl)acetamide
- CAS Number: 143360-00-3
- Molecular Formula: C13H19NO
- Molecular Weight: 205.29600
- Catalog: Signaling Pathways Apoptosis Apoptosis
- Create Date: 2018-12-31 19:35:28
- Modify Date: 2024-01-10 16:33:07
-
SMIP004 is a novel inducer of cancer-cell selective apoptosis of human prostate cancer cells, it was found to downregulate SKP2 and to stabilize p27.IC50 Value: 1.09 uM (MTT assay in LNCaP-S14 cells) [1]Target: Apoptosis inducer; SKP2in vitro: Whereas SMIP012 and 016 were moderately toxic in normal fibroblasts, SMIPs 001 and 004 showed substantial cancer cell specificity being at least five times more potent in LNCaP-S14 than in IMR90 cells , treatment with either MG132 or SMIP004 increased p27 half-life to > 6 h [1]. Both SMIP001 and 004 led to a strong increase in the recruitment of p27 to CDK2, while SMIP001 also slightly increased coprecipitation of p21 (Figure 6c). SMIP004 also reduced the amounts of cyclins E and A retrieved with CDK2. This was paralleled by a marked downregulation of cyclins E and A upon SMIP004 treatment. SMIP004 decreased the levels of positive cell cycle regulators, upregulated cyclin-dependent kinase inhibitors, and resulted in G1 arrest, inhibition of colony formation in soft agar, and cell death [2].in vivo: SMIP004 potently inhibits the growth of prostate and breast cancer xenografts in mice [2].Clinical trial:
| Name | N-(4-butyl-2-methylphenyl)acetamide |
|---|---|
| Synonyms |
acetic acid-(4-butyl-2-methyl-anilide)
Essigsaeure-(4-butyl-2-methyl-anilid) Acetamide,N-(4-butyl-2-methylphenyl) 6-Acetamino-3-butyl-toluol 2-methyl-4-butylacetanilide N1-(4-butyl-2-methylphenyl)acetamide SMIP004 |
| Description | SMIP004 is a novel inducer of cancer-cell selective apoptosis of human prostate cancer cells, it was found to downregulate SKP2 and to stabilize p27.IC50 Value: 1.09 uM (MTT assay in LNCaP-S14 cells) [1]Target: Apoptosis inducer; SKP2in vitro: Whereas SMIP012 and 016 were moderately toxic in normal fibroblasts, SMIPs 001 and 004 showed substantial cancer cell specificity being at least five times more potent in LNCaP-S14 than in IMR90 cells , treatment with either MG132 or SMIP004 increased p27 half-life to > 6 h [1]. Both SMIP001 and 004 led to a strong increase in the recruitment of p27 to CDK2, while SMIP001 also slightly increased coprecipitation of p21 (Figure 6c). SMIP004 also reduced the amounts of cyclins E and A retrieved with CDK2. This was paralleled by a marked downregulation of cyclins E and A upon SMIP004 treatment. SMIP004 decreased the levels of positive cell cycle regulators, upregulated cyclin-dependent kinase inhibitors, and resulted in G1 arrest, inhibition of colony formation in soft agar, and cell death [2].in vivo: SMIP004 potently inhibits the growth of prostate and breast cancer xenografts in mice [2].Clinical trial: |
|---|---|
| Related Catalog | |
| References |
| Density | 1.003g/cm3 |
|---|---|
| Boiling Point | 343ºC at 760mmHg |
| Molecular Formula | C13H19NO |
| Molecular Weight | 205.29600 |
| Flash Point | 206.1ºC |
| Exact Mass | 205.14700 |
| PSA | 29.10000 |
| LogP | 3.36900 |
| Vapour Pressure | 7.24E-05mmHg at 25°C |
| Index of Refraction | 1.539 |
| Storage condition | 2-8℃ |
| HS Code | 2924299090 |
|---|
| HS Code | 2924299090 |
|---|---|
| Summary | 2924299090. other cyclic amides (including cyclic carbamates) and their derivatives; salts thereof. VAT:17.0%. Tax rebate rate:13.0%. . MFN tariff:6.5%. General tariff:30.0% |